If you are diagnosed with cancer, don’t avoid it. Get treated and stay safe.

Ovarian Cancer is cancer that starts in the ovaries and although it starts there, it does have potential to spread. The exact cause for ovarian cancer is unknown, but is well known that DNA mutation is primary cause of any type of cancer. This cancer is the second most common type of cancer among women across the world, while fifth leading cause of  death related to cancer like disease. Immunotherapy may helps to patients to receive a high quality treatment for the cancer.  

Ovarian Cancer is said to be the 10th most common cancer in women and is more likely to lead to death than any other cancer that affects a woman's reproductive system (ranking fifth in cancers that kill women). Ovarian Cancer is known as the silent killer because most times symptoms go unnoticed and unattended too. Generally, the most serious symptoms occur in the late stages of ovarian cancer. Ovarian cancer is rarely diagnosed in its early stages.

www.gapsos.com

It is estimated that about 3 out of 4 women survive ovarian cancer after a year’s diagnosis. About half of the women with ovarian cancer live longer than 5 years, especially if they are diagnosed and treated early.

It is important to know the symptoms of ovarian cancer so that you will be able to detect it early if possible. Several symptoms are notified that involve bloating, abdominal pain, vaginal bleeding, change in menstrual cycle, pelvic pain, nausea or vomiting, back pain that increases constipation, indigestion, swollen abdomen or belly, while decrease in appetite, and increase in bathroom use, increase in hair growth, and an increase or decrease in weight gain.

In immunotherapy, various types of immunotherapeutic cancer agents are involved like monoclonal antibody drugs, therapeutic vaccines, and adoptive T cell therapy. Bevacizumab is a monoclonal antibody drug has received approval by the Food and Drug Administration (FDA) for the treatment of this cancer in the combination with ADC,Topotecan, and  Paclitaxel. FDA concludes none of the contraindication with this drug, while some warnings are mentioned like hemorrhage and gastrointestinal perforations. Some common adverse effects are observed like headache and back pain.Much more immunotherapeutic cancer agents are under evaluation for FDA approval via clinical trials such as Ipilimumab, MORAb-003, OVAX,Natural killer cells, and NY-ESO-1 reactive.

Uterine cancer patients can be treated with advanced treatment such as immunotherapy.

Uterine cancer is one the leading causes of death related to cancer like disease across the world. The majority of uterine cancer is adenocarcinomas which include serous, mucinous, clear cell, and mixed cell. The epithelial non adenocarcinomas include squamous cell carcinoma, small cell carcinoma, transitional cell carcinoma, and undifferentiated carcinoma. Immunotherapy treatments have various immunotherapeutic cancer agents which are used in all types of this cancer.

www.gapsos.com

Several risk factors are observed that involve age (postmenopausal after the age of 55 years, incidence rate is higher than 95 per 100,000 people in the age of 65 Years), endogenous estrogen exposure ( it causes early menarche, nulliparity, infertility, late menopause, and estrogen producing tumor), exogenous estrogen (Hormonal ReplacementTherapy and drugs such as  Tamoxifen), past medical history (diabetes mellitus, and hypertension), history of endometrial atypical hyperplasia, family history (less than 1% of uterine cancer is due to familial factors), history of breast cancer, and genetic factors (mutations in the MLH1 or MSH2 Gene cause of defect in hereditary nonpolyposis colorectal cancer  have 20% risk to developing endometrial cancer before the age of 50 years, and 60% risk after the age of 60 years)

Various symptoms were observed in the advanced stage of this cancer that involves vaginal bleeding in unexpected postmenopausal women (menorrhagia or metrorrhagia ).Profuse watery discharge is another symptoms.Attention should be paid to the duration and severity of the symptoms.

The significant role play by immunotherapeutic cancer agent in Immunotherapy for  the treatment of uterine cancer that involve monoclonal antibody drug, vaccine based immunotherapy, adoptive T cell therapy. Kinase inhibitors, cytokines, and checkpoint inhibitors. These immunotherapeutic cancer agents have common actions that are increasing the potential of patient’s immune system to fight with specific cancer’s cell. In the present time, no single immunotherapy based drug has received approval by the Food and Drug Administration (FDA) for the treatment of this cancer, but much more are under evaluation via passes through several pre clinical and clinical phases (phase 1, phase 2, and phase 3) for FDA approval.

Bevacizumab is a monoclonal antibody drug  is running in clinical trials (phase 2) under evaluation of safety and efficacy, and for FDA approval. This drug inhibits the growth of specific cancer’s cell via blocking the way of blood flow to the site of cancer. 

Global Allied pharmaceuticals (GAP) have number of immunotherapeutic cancer agents for the treatment of cancer like disease such as uterine. GAP has a responsible team of expert for immunotherapy and antibody drug conjugates.

For more information kindly visit us at www.gapsos.com

Immunotherapy increase the level of treatment for cervical cancer.

A slow growing cancercan be asymptomatic in early stages. Cells of the cervix become abnormal and start to grow uncontrollably, forming tumors. Preceded by dysplasia, it changes precancerous on the cervix, towards invasive carcinoma.In United States, accounts for 86% of all cancers in women and the peak incidence between the age range of 50 to 55 years. The second most common cancer in the United States with more than 400,000 new cases diagnosed each year. It is observed that the incidence is very high in developing countries.Now, immunotherapy drug uses to saves more lives of cervical cancer patients.

 

www.gapsos.com

Human Papilloma Virus (HPV) spreads through sexual intercourse; it is high risk strains 16 and 18, which cause 70% of all cervical cancer. Other risk factors include having sex an early age, multiple sexual partners, use of diethylstilbestrol drug during pregnancy, long term use of birth control pills, compromised immune system, infections with genital herpes or chronic chlamydial, poor living standards, smoking, and multiple pregnancies.

Early cervical cancer may be asymptomatic, but symptoms include continuous discharge from vagina, abnormal bleeding through vagina during periods, after intercourse, bleeding after menopause, longer and heavier periods than usual.Symptoms of advanced cervical cancer include pelvic pain, fatigue, back pain, single swollen leg, leg pain, heavy bleeding from the vagina, leakage of urine or feces from the vagina, bone fracture, and loss of appetite and weight loss.

This cancer isclassified into six histological types that involve Squamous cell carcinoma (85-90%, rise from ectocervix), Adenocarcima (10-15%, rise from endocervix, common in young groups), Adenosquamous (mix of endometriod and clear cell), Adenomamalignum (extremely well differentiated adenocarcinoma), Small cell carcinoma, and neuroendocrine carcinoma.

The Food and Drug Administration (FDA) approved many immunotherapeutic cancer agents for the treatment of cervical cancer after evaluation under clinical trials. Bevacizumab has received FDA approval for the treatment of metastatic condition of this cancer, in combination with Topotecan and Paclitaxel. Many immunotherapeutic cancer agents are still under evaluation of clinical trials for FDA approval such as ADXS11-001 (Lm-LLO-E7), E6 TCR, and HPV16 E7 peptide-pulsed autologous DCs.

Global Allied Pharmaceuticals (GAP) has new technology to developed advanced treatment based on immunotherapy and antibody drug conjugate. GAP has experts for conducting experiments and clinical trials of newly developed immunotherapeutic cancer agents that involves monoclonal antibodies, therapeutic vaccines, adoptive T cell therapy and many more.

Immunotherapy rises as new approach toward breast cancer treatment.

Breast cancer is found as the second most common cancer in women in the United States, while it is one of the leading causes of cancer death across the world. With the availability of advance treatment based on immunotherapy and presence of the new technology for diagnosis, may help in early detection of this cancer.

Fibrocystic breast changes term used to describe certain benign changes in the breast, typically associated with palpable nodularity, lumpiness, swelling, or pain. Lymph edema is chronic swelling of an extremity due to axillary lymph node dissection. Mastitis is inflammation or infection of the breast. Paget’s disease from of breast cancer begins in the ductal system and involves the nipple, areola, and surrounding skin. Gynecomastia is over developed breast tissue typically seen in adolescent boys.

Types of breast cancer involve in situ breast cancer and infiltrating breast cancer.

In Situ Breast Cancer remains within the ducts or lobules of the breasts. This type of cancer is not easily detected. In Ductal Carcinoma in situ (DCIS), cancer is arises in the milk duct. In Lobular Carcinoma in situ (LCIS), cancer is arises in the lobule of the breast. LCIS is most common cancer, in the case of pre-menopausal in women.

www.gapsos.com

 

Breast cancer cells cross the lining of the lobule or milk duct, and begin to invade adjacent tissues, it is known as infiltrating cancer. Breast cancer is considered infiltrating or invasive, when the cancer cells have penetrated the membrane that surrounds a duct or lobule. This type of cancer forms a lump that can eventually be felt by a physical examination.

There are several immunotherapy are used for treatment of breast cancer. This therapy is based on several immunotherapeutic cancer agents such as monoclonal antibodies. Therapeutic vaccines, kinase inhibitor and miscellaneous. Some of them  (Trastuzumab and Pertuzumab) have received Food and Drug Administration (FDA) approval  for the treatment of this cancer, while many (Margetuximab, Bevacizumab, and Glembatumumab Vedotin) are under various phases of clinical trials for FDA approval.

Global Allied Pharmaceuticals (GAP) has new technology for diagnosis, which is primary requirement for management of disease. GAP has a panel of experts for immunotherapy and immune oncology. Our experts provide suitable therapy to patients on the basis of disease diagnosis result.

CLINICAL AFFAIRS: Yes that’s what we deal with!

Clinical and Medical affairs details with the Healthcare Regulatory Authority. It helps the healthcare industries for safety and efficiency of the clinical products, therapies and medical devices etc. Medical Affairs team works closely with the clinical development team for planning and organizing clinical trials. They support Clinical development plan and protocol, ongoing data maintenance and statistical analysis and report writing activities. Medical Affairs identify and address the medical needs associated with products, therapies and disease states thereby driving improvement in patient outcomes in line with commercial objectives. However with time, the role of Medical Affairs has transformed from being a traditional support function to an equal partner role. Besides providing scientific and medical information to healthcare professionals, key opinion leaders and regulatory bodies.

Medical Affairs provides consulting services to sales & marketing, clinical trials, pharmacovigilance, regulatory and legal departments. The role of medical affairs function is to educate the healthcare professionals through the delivery of precise, complete and impartial information that supports a product. The medical and clinical expertise required in the Clinical and Medical Affairs function can lead to continuing growth and advancement throughout the organization.

 

Clinical and medical affairs professionals have an opportunity to work as part of a global, cross-functional team to make a meaningful difference in the lives of patients with cancer, immune disorders, kidney disease and other chronic and acute conditions.

Medical affairs professionals interact with a range of functional areas across the company, including Manufacturing, Quality, Regulatory Affairs and Pharmacovigilance, Research and Development, and Marketing. Medical Affairs plays an important role in promoting proper and ethical use of a company's products and therapies for the benefit of mankind.

 Thus, Medical Affairs function supplements the work of Research & Development and also enhances sales and marketing writing. Medical writing has established as an important function of Medical Affairs, because it requires specialized knowledge and skills to write scientific documents which are well-structured, and presented in a clear and lucid manner. Medical Affairs professionals evaluate and conduct pharmacoeconomic studies to facilitate cost effective health care decision making. The complexity of medical marketing is one of the important aspects of a business proposal in the pharmaceutical industry. The Medical Affairs provides guidance on therapy positioning in all marketing and promotional campaigns and keep a close watch on the approvals. Medical Affairs activities ensure appropriate market conditioning which has a real impact on increasing product awareness.

For more details -Visit www.gapsos.com